Clinical evaluation of Midecamycin acetate (MOM) in odontogenic infection

Clinical efficacy and safety of Midecamycin acetate (MOM) were compared with those of Josamycin (JM) in patients with oral and maxillofacial infections under multicentered double-blind controlled study, and the following results were obtained.1. The overall clinical effectiveness rate was 77.4% for MOM group and 77.4% for JM group, judged by committee members with no significant difference.2. Clinical effectiveness rate classified by diagnosis was 78.8% for MOM group and 78.0% for JM in periodontal infections but no significant difference was observed.In pericoronitis, clinical effectiveness rate was 76.3% for MOM and 62. 5% for JM, but no significant difference was observed.In osteitis of jaws, clinical effectiveness rate was 76.3% for MOM and 85.9% for JM, but no significant difference was observed.3. As to improvement rate of clinical signs and symptoms, no significant difference was observed.4. Some side effects were observed in 7 patients (3.3%) in the MOM group and 12 patients (5.6%) in the JM group with no significant intergroup difference in incidence of these side effects.5. Some abnormal laboratory findings were observed in 4 patients (4%) in the MOM group and one patient (0.9%) in the JM group with no significant intergroup difference in incidence of these abnormal laboratory findings.6. The clinical usefulness rate judged by doctors in charge was 72.9% for MOM group and 76.2% for JM group, with no significant difference.From the above results, it was concluded that MOM had the same efficacy as JM for the treatment of oral and maxillofacial infections with half doses of JM.